Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Colchicine pre-PCI improves biomarkers, not injury risk

Key clinical point: Oral colchicine before percutaneous coronary intervention has no preventive effect, compared with placebo.

Major finding: Rates of PCI-related myocardial injury were 57.3% and 64.2% in the colchicine and placebo groups, respectively.

Study details: Investigator-initiated, single-site prospective randomized double-blind study of 400 patients from COLCHICINE-PCI trial randomized to treatment or placebo.

Disclosures: Dr. Shah disclosed financial relationships with Phillips Volcano and Radux. The VA Office of Research and Development and AHA provided grant funding and Takeda provided the drug.

Citation:

Shah B. AHA 2019, Late Breaking Science session IV.